Eli Lilly and - Stock

Eli Lilly and Revenue 2024

Eli Lilly and Revenue

43.49 B USD

Ticker

LLY

ISIN

US5324571083

WKN

858560

In 2024, Eli Lilly and's sales reached 43.49 B USD, a 27.44% difference from the 34.12 B USD sales recorded in the previous year.

The Eli Lilly and Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e85.9131,48
2028e79.3834,06
2027e70.5538,33
2026e63.6542,48
2025e53.6550,41
2024e43.4962,18
202334.1279,25
202228.5476,77
202128.3274,18
202024.5477,66
201922.3278,84
201821.4978,22
201719.9777,73
201621.2273,35
201519.9674,76
201419.6274,85
201323.1178,77
201222.678,78
201124.2979,13
201023.0881,08
200921.8480,55
200820.3778,51
200718.6377,20
200615.6977,40
200514.6576,28
200413.8676,74

Eli Lilly and Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Eli Lilly and, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Eli Lilly and from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Eli Lilly and’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Eli Lilly and. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Eli Lilly and’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Eli Lilly and’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Eli Lilly and’s growth potential.

Eli Lilly and Revenue, Profit, and EBIT History

DateEli Lilly and RevenueEli Lilly and EBITEli Lilly and Net Income
2029e85.91 B undefined0 undefined37.42 B undefined
2028e79.38 B undefined35.22 B undefined33.46 B undefined
2027e70.55 B undefined29.93 B undefined28.49 B undefined
2026e63.65 B undefined27.2 B undefined24.36 B undefined
2025e53.65 B undefined20.85 B undefined18.51 B undefined
2024e43.49 B undefined14.9 B undefined13.22 B undefined
202334.12 B undefined10.33 B undefined5.24 B undefined
202228.54 B undefined8.28 B undefined6.25 B undefined
202128.32 B undefined7.55 B undefined5.58 B undefined
202024.54 B undefined6.85 B undefined6.19 B undefined
201922.32 B undefined5.79 B undefined8.32 B undefined
201821.49 B undefined5.79 B undefined3.23 B undefined
201719.97 B undefined4.45 B undefined-204 M undefined
201621.22 B undefined3.87 B undefined2.74 B undefined
201519.96 B undefined3.59 B undefined2.41 B undefined
201419.62 B undefined3.33 B undefined2.39 B undefined
201323.11 B undefined5.55 B undefined4.69 B undefined
201222.6 B undefined5.02 B undefined4.09 B undefined
201124.29 B undefined6.32 B undefined4.35 B undefined
201023.08 B undefined6.77 B undefined5.07 B undefined
200921.84 B undefined6.37 B undefined4.33 B undefined
200820.37 B undefined5.53 B undefined-2.07 B undefined
200718.63 B undefined4.8 B undefined2.95 B undefined
200615.69 B undefined4.13 B undefined2.66 B undefined
200514.65 B undefined3.65 B undefined1.98 B undefined
200413.86 B undefined3.66 B undefined1.81 B undefined

Eli Lilly and stock margins

The Eli Lilly and margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Eli Lilly and. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Eli Lilly and.
  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Eli Lilly and's sales revenue. A higher gross margin percentage indicates that the Eli Lilly and retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Eli Lilly and's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Eli Lilly and's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Eli Lilly and's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Eli Lilly and. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Eli Lilly and's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Eli Lilly and Margin History

Eli Lilly and Gross marginEli Lilly and Profit marginEli Lilly and EBIT marginEli Lilly and Profit margin
2029e79.25 %0 %43.55 %
2028e79.25 %44.37 %42.15 %
2027e79.25 %42.43 %40.39 %
2026e79.25 %42.74 %38.28 %
2025e79.25 %38.86 %34.5 %
2024e79.25 %34.26 %30.4 %
202379.25 %30.26 %15.36 %
202276.77 %29.01 %21.88 %
202174.18 %26.65 %19.71 %
202077.66 %27.91 %25.24 %
201978.84 %25.94 %37.27 %
201878.22 %26.92 %15.04 %
201777.73 %22.26 %-1.02 %
201673.35 %18.25 %12.9 %
201574.76 %18 %12.06 %
201474.85 %16.97 %12.19 %
201378.77 %24 %20.27 %
201278.78 %22.19 %18.09 %
201179.13 %26.01 %17.9 %
201081.08 %29.35 %21.97 %
200980.55 %29.17 %19.83 %
200878.51 %27.13 %-10.17 %
200777.2 %25.78 %15.85 %
200677.4 %26.3 %16.97 %
200576.28 %24.91 %13.52 %
200476.74 %26.4 %13.06 %

Eli Lilly and Aktienanalyse

What does Eli Lilly and do?

Eli Lilly and Co. is a global biopharmaceutical company headquartered in Indianapolis, Indiana, USA. The company was founded in 1876 by Colonel Eli Lilly with the aim of manufacturing pharmaceutical products of the highest quality. Eli Lilly began his career in the pharmacy industry and opened his own pharmacy in Indianapolis in 1876. He quickly developed his own medications and eventually established Eli Lilly and Company in 1901. Over the years, the company has continued to evolve and expand its business into numerous areas. Eli Lilly is focused on biopharmaceutical research and development and operates in areas such as oncology, diabetes, neurology, and others. The company's main goal is to develop drugs that can change and improve lives. Eli Lilly invests a high percentage of its revenue into research and development every year. The company has several strategic business units, including human pharmaceuticals, animal pharmaceuticals, and oncology research. Eli Lilly is divided into five main divisions: diabetes, oncology, immunology, neurology, and animal health. The diabetes division focuses on manufacturing insulin products and glucose sensors for the treatment of type 1 and type 2 diabetes, as well as blood glucose meters and other diabetes products. The oncology division focuses on researching and developing drugs to treat cancer. The company currently has several compounds in clinical trials, including a new preparation for the treatment of breast cancer. The immunology division focuses on products for the treatment of autoimmune and inflammatory diseases, such as psoriasis. The neurology division focuses on researching and developing drugs to treat diseases of the nervous system, such as Alzheimer's. The animal health division focuses on animal health products, such as drugs for the treatment of infections in livestock and pets. Eli Lilly is primarily known for its insulin products and treatments in the field of oncology. Some of the company's most well-known products include Humalog, Forteo, Alimta, and Cymbalta. The effectiveness and compliance of the products are monitored by a quality and safety system to ensure that patients receive the highest quality medications. In conclusion, Eli Lilly and Co. is a company with a long history and a unique business model. The company specializes in developing high-quality pharmaceutical products and has continued to evolve since its founding. Eli Lilly has become a leader in various areas such as diabetes, oncology, immunology, neurology, and animal health. They are known for their insulin products and treatments in the field of oncology. The company remains committed to expanding its reach and presence globally and continues to develop innovative products that can improve and change people's lives. Eli Lilly and ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Eli Lilly and's Sales Figures

The sales figures of Eli Lilly and originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Eli Lilly and’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Eli Lilly and's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Eli Lilly and’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Eli Lilly and Stock

How much revenue did Eli Lilly and generate this year?

Eli Lilly and has achieved a revenue of 43.49 B USD this year.

How much was the turnover of the company Eli Lilly and compared to the previous year?

The revenue of Eli Lilly and has increased by 27.44% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Eli Lilly and?

The revenue of Eli Lilly and is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Eli Lilly and measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Eli Lilly and so important for investors?

The revenue of Eli Lilly and is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Eli Lilly and pay?

Over the past 12 months, Eli Lilly and paid a dividend of 4.52 USD . This corresponds to a dividend yield of about 0.51 %. For the coming 12 months, Eli Lilly and is expected to pay a dividend of 5.73 USD.

What is the dividend yield of Eli Lilly and?

The current dividend yield of Eli Lilly and is 0.51 %.

When does Eli Lilly and pay dividends?

Eli Lilly and pays a quarterly dividend. This is distributed in the months of September, December, March, June.

How secure is the dividend of Eli Lilly and?

Eli Lilly and paid dividends every year for the past 26 years.

What is the dividend of Eli Lilly and?

For the upcoming 12 months, dividends amounting to 5.73 USD are expected. This corresponds to a dividend yield of 0.65 %.

In which sector is Eli Lilly and located?

Eli Lilly and is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eli Lilly and kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eli Lilly and from 6/10/2024 amounting to 1.3 USD, you needed to have the stock in your portfolio before the ex-date on 5/15/2024.

When did Eli Lilly and pay the last dividend?

The last dividend was paid out on 6/10/2024.

What was the dividend of Eli Lilly and in the year 2023?

In the year 2023, Eli Lilly and distributed 3.92 USD as dividends.

In which currency does Eli Lilly and pay out the dividend?

The dividends of Eli Lilly and are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Eli Lilly and stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank

Andere Kennzahlen von Eli Lilly and

Our stock analysis for Eli Lilly and Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eli Lilly and Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.